News
-
-
PRESS RELEASE
Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m
Crossject launches reserved capital increase and warrants issuance for at least €7 million, engaging with investors through private placement. Transaction details disclosed for immediate new funding to support ZEPIZURE® development -
-
PRESS RELEASE
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement
Crossject and the U.S. Department of Defense extend their cooperative research on needle-free autoinjectors, aiming to provide life-saving treatment in extreme conditions -
-
-
-
-
-
PRESS RELEASE
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Crossject provides insights on ZEPIZURE® potential in light of RAMPART and its bioequivalence study. IM midazolam favored over IV lorazepam for emergency epilepsy management
